An FDA advisory committee said Sanofi's Lemtrada, or alemtuzumab, was not so risky that it precluded approval as a treatment for multiple sclerosis. The drug, however, should not be used for first-line treatment, the panel said. The agency is set to issue a decision by Dec. 27.
FDA advisers say Sanofi's MS drug Lemtrada can be approved
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan